In contrast, in a retrospective study by Borowczyk et al. in 2014, JAK2 V617F allelic burden in 126 patients with Ph- MPN and the mutation was analyzed with the intention of assessing its role in the risk stratification of future vascular complications. This evidence concerns the gene JAK2 and myeloproliferative disorder.